We are live on ! Find out more
CS

Candriam SCA Portfolio holdings

AUM $19.3B
1-Year Est. Return 39.18%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.82B
AUM Growth
+$1.31B
Cap. Flow
+$158M
Cap. Flow %
2.03%
Top 10 Hldgs %
19.27%
Holding
869
New
65
Increased
350
Reduced
240
Closed
81

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$43.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$30.4M
3
GILD icon
Gilead Sciences
GILD
+$28.3M
4
BIIB icon
Biogen
BIIB
+$26.7M
5
GOOGL icon
Alphabet (Google) Class A
GOOGL
+$25.2M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$75.2M
2
LOXO
Loxo Oncology, Inc
LOXO
+$28.1M
3
DHR icon
Danaher
DHR
+$27.9M
4
A icon
Agilent Technologies
A
+$26.4M
5
MKC icon
McCormick & Company Non-Voting
MKC
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 33.36%
2 Technology 15.96%
3 Financials 11.25%
4 Consumer Discretionary 8.98%
5 Communication Services 7.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMAT icon
51
Applied Materials
AMAT
$426B
$28.4M 0.36%
688,129
-326,238
-32% -$12.4M
SAGE
52
DELISTED
Sage Therapeutics
SAGE
$28.4M 0.36%
178,300
+18,000
+11% +$2.61M
IBM icon
53
IBM
IBM
$202B
$28.2M 0.36%
196,173
-30,943
-14% -$3.94M
PRU icon
54
Prudential Financial
PRU
$41.7B
$27.4M 0.35%
279,855
+56,190
+25% +$5.18M
ADSK icon
55
Autodesk
ADSK
$44.3B
$27.3M 0.35%
174,896
+11,464
+7% +$1.71M
TJX icon
56
TJX Companies
TJX
$170B
$26.7M 0.34%
475,022
+96,771
+26% +$4.83M
ALNY icon
57
Alnylam Pharmaceuticals
ALNY
$36.3B
$26.6M 0.34%
284,701
– –
BLUE
58
DELISTED
bluebird bio
BLUE
$26.6M 0.34%
13,055
– –
BZUN
59
Baozun
BZUN
$144M
$26.6M 0.34%
+640,000
New +$22.4M
UNP icon
60
Union Pacific
UNP
$183B
$26.5M 0.34%
149,386
+8,331
+6% +$1.34M
WFC icon
61
Wells Fargo
WFC
$261B
$26.3M 0.34%
481,221
+3,625
+0.8% +$178K
NBIX icon
62
Neurocrine Biosciences
NBIX
$17.7B
$25.8M 0.33%
292,669
+64,600
+28% +$5.4M
SHW icon
63
Sherwin-Williams
SHW
$78.3B
$25.5M 0.33%
177,507
+7,401
+4% +$1.03M
MMM icon
64
3M
MMM
$89B
$25.4M 0.32%
146,114
+38,138
+35% +$6.42M
GG
65
DELISTED
Goldcorp Inc
GG
$24.9M 0.32%
2,173,515
+1,699,002
+358% +$18.2M
ALL icon
66
Allstate
ALL
$66.9B
$24.6M 0.31%
247,971
-11,408
-4% -$1.03M
KO icon
67
Coca-Cola
KO
$354B
$24.4M 0.31%
490,590
+165,729
+51% +$7.75M
TXN icon
68
Texas Instruments
TXN
$255B
$24.2M 0.31%
209,312
+65,643
+46% +$6.8M
ONC
69
BeOne Medicines Ltd
ONC
$33.8B
$24.2M 0.31%
183,232
+35,444
+24% +$4.78M
LLY icon
70
Eli Lilly
LLY
$1.07T
$23.5M 0.3%
181,004
+33,302
+23% +$4.05M
DHR icon
71
Danaher
DHR
$135B
$23.2M 0.3%
198,578
-272,152
-58% -$27.9M
BAP icon
72
Credicorp
BAP
$30.9B
$23M 0.29%
95,700
+7,400
+8% +$1.76M
SRPT icon
73
Sarepta Therapeutics
SRPT
$1.66B
$23M 0.29%
192,600
+66,500
+53% +$8.55M
RARX
74
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$22.9M 0.29%
1,024,000
+145,000
+16% +$3.12M
TRMB icon
75
Trimble
TRMB
$12.3B
$22.8M 0.29%
565,070
-2,024
-0.4% -$76.8K
1 2
3
4 5

Similar funds

PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
A
AustralianSuper Melbourne, Australia $19.2B AUM 31.95% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $19.4B AUM 16.7% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
SOMRS
State of Michigan Retirement System Lansing, Michigan $18.9B AUM 27.96% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return

Candriam SCA's Q1 2019 Portfolio in Review

As of Q1 2019, Candriam SCA held 869 positions worth $7.82B, up 20% from $6.51B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Candriam SCA's Q1 2019 filing shows 65 new, 350 increased, 240 reduced and 81 closed positions. Its largest new stake was Baozun: 640,000 shares worth $26.6M. The largest sale was Celgene Corp, an estimated $75.2M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 35% a quarter earlier, followed by Technology and Financials.

  • Candriam SCA's largest Q1 2019 buy was Baozun: 640,000 shares worth $26.6M.
  • Candriam SCA added most to Merck in Q1 2019, an estimated $43.7M increase.
  • Candriam SCA's biggest Q1 2019 reduction was Celgene Corp, cutting an estimated $75.2M.
  • Candriam SCA fully exited Loxo Oncology, Inc in Q1 2019, selling an estimated $28.1M.
  • Candriam SCA's ten largest holdings make up 19% of its $7.82B portfolio in Q1 2019.
  • Candriam SCA opened 65 new positions and closed 81 in Q1 2019.
  • Candriam SCA's portfolio value rose 20% quarter-over-quarter to $7.82B.

Based on Candriam SCA's 13F filing for Q1 2019, filed 2 May 2019.